Zymeworks (ZYME) Stock Price, News, Quotes-Moomoo

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

Zymeworks (NASDAQ:ZYME) Is In A Good Position To Deliver On Growth Plans
Yahoo Finance43minutes ago
More Unpleasant Surprises Could Be In Store For Zymeworks Inc.'s (NASDAQ:ZYME) Shares After Tumbling 27%
Simply Wall St05:53 ET
Zymeworks Advances Oncology and Expands Therapeutic Reach
TipRanksDec 12 09:08 ET
Zymeworks Hosts R&D Day Highlighting Continued Clinical Progress In Oncology Programs And Expansion Into Autoimmune And Inflammatory Diseases December 12, 2024 At 8:30 Am EST
BenzingaDec 12 08:54 ET
Catalyst Watch: Goldman Sachs Finance Conference; Adobe, CostCo Earnings
Seeking AlphaDec 6 15:00 ET
Express News | HC Wainwright & Co. Reiterates Neutral on Zymeworks, Maintains $12 Price Target
BenzingaNov 22 06:54 ET

Comments

Meltyy

Nov 26 01:17

🚨 1 PDUFA this week!

See FDA PDUFA update 👇
$Applied Therapeutics (APLT.US)$ : 🤔
⇨ Govorestat
‣ Classic Galactosemia
‣ PDUFA: 11/28/24 (NDA)
🗓️ Last Week’s Adcom & PDUFA decisions:
$BridgeBio Pharma (BBIO.US)$ : Approved 11/22 ✅
⇨Attruby (Acoramidis)
‣ ATTR-CM (transthyretin amyloid cardiomyopathy)
‣ PDUFA: 11/29/24 (NDA)
$AstraZeneca (AZN.US)$ : Discussion, no vote
⇨ Andexxa (coagulation factor Xa)
‣ Life-threatening or uncontrolled bleeding
‣ Adcom: 11/21/24 (sBLA)
$Jazz Pharmaceuticals (JAZZ.US)$ & $Zymeworks (ZYME.US)$ : Approve...

7

1

Jaguar8

Jul 22 05:03

NEWS

$Zymeworks (ZYME.US)$
Zymeworks Announces FDA Clearance of Investigational New Drug Application for ZW191, a Novel Folate Receptor-⍺ Targeted Topoisomerase I Inhibitor Antibody-Drug Conjugate
Zymeworks Inc. (Nasdaq: ZYME) announced FDA clearance of its Investigational New Drug (IND) application for ZW191, a novel folate receptor-⍺ (FR⍺) targeted topoisomerase I inhibitor antibody-drug conjugate (ADC). ZW191 targets FR⍺-expressing tumors, including ovarian, gynecological cancers, and non-small...

Jaguar8

Jun 17 06:42

NEWS

$Zymeworks (ZYME.US)$
Zymeworks Announces FDA Clearance of Investigational New Drug Application for ZW171, a novel 2+1 T-cell Targeting Bispecific Antibody for Mesothelin-expressing Cancers
Zymeworks (Nasdaq: ZYME) announced that the FDA has cleared its investigational new drug (IND) application for ZW171, a novel 2+1 T-cell targeting bispecific antibody designed to treat mesothelin (MSLN)-expressing cancers such as ovarian cancer, non-small cell lung cancer, and mesothelioma. ZW171 aims to i...

1